Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
On November 8, 2022, Clarivate Plc (NYSE: CLVT; CLVT PR A) declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. This dividend is payable in cash on December 1, 2022 to shareholders recorded as of the close of business on November 15, 2022. Clarivate continues to affirm its commitment to delivering value to its shareholders through consistent dividend payments.
Clarivate reported Q3 2022 revenues of $635.7 million, marking a 43.8% increase, driven by the acquisition of ProQuest. However, a significant non-cash goodwill impairment led to a net loss of $4,434.4 million, with a net loss per share of $6.64. Organic revenue growth was 1.2%, with subscription revenues rising 65.6%, but transactional revenues declined 9.4%. Adjusted net income was $143.7 million, up 26.5%. The company generated $372.4 million in cash from operations.
Clarivate Plc (NYSE: CLVT) announced a settlement with OCLC regarding allegations of misconduct, which Clarivate firmly denies. The agreement emphasizes the importance of collaborative platforms for bibliographic records, with Clarivate agreeing to not develop a MARC records exchange system that conflicts with OCLC's policies. This settlement is aimed at supporting the goals of open research and data exchange, facilitating a more efficient research process. Clarivate will cover its own legal fees related to this settlement.
Newfold Digital has successfully acquired MarkMonitor™, an enterprise-level domain management provider, from Clarivate Plc (NYSE:CLVT) as of November 1, 2022. The acquisition enhances Newfold's capabilities in establishing and protecting online presence for businesses. CEO Sharon Rowlands emphasized MarkMonitor’s expertise and commitment to security, aiming for ongoing improvements in customer service. This is part of Newfold's strategy to expand its product offerings and enhance customer experience across its global operations.
On November 1, 2022, Clarivate Plc (NYSE:CLVT) announced the successful divestiture of MarkMonitor™ to Newfold Digital for $302.5 million. This strategic move allows Clarivate to concentrate on its core intellectual property portfolio. The net cash proceeds will aid in reducing outstanding debt, enhancing the company's financial position. The deal was previously announced on September 12, 2022, and aligns with Clarivate's mission to accelerate innovation through focused investments.
Clarivate Plc (CLVT) released a report highlighting that innovation in sustainable energy is declining, particularly in solar and wind power, which are nearing technical maturity. Although these energies have seen significant research over the last three decades, the report suggests that activity is slowing down. Oceanic power is still developing, showing potential but currently lacking maturity.
China leads in renewable energy innovation, outpacing the U.S. in patent activity. The study provides insights into research gaps and trends, aligning with global sustainability goals.
Clarivate Plc (NYSE:CLVT) has released a report titled RNA Technology Companies to Watch, highlighting seven innovative companies in the RNA technology space. These firms are addressing undruggable disease targets, demonstrating potential benefits such as fewer side effects and enhanced efficacy. The report notes a significant increase in RNA-related scientific research and patent filings, with the U.S. and Mainland China leading advancements. Despite challenges in RNA stability and delivery, the sector remains promising.
Clarivate Plc (NYSE:CLVT) published a report analyzing formal regional research assessment systems across Australia, Canada, Germany, Hong Kong, New Zealand, and the UK. The report indicates improvements in comparative research performance but lacks a consensus on whether research assessment is essential. Key insights include Australia's unique methodology, Canada's focus on knowledge mobilization, and the UK's historical role in establishing research assessment models. The report also highlights potential biases in AI-driven assessments and their implications for the research ecosystem.
Summary not available.
On Sept. 28, 2022, Clarivate Plc (NYSE: CLVT) announced it will report its third quarter 2022 financial results on November 8, 2022, before market opening. A conference call at 9:00 AM ET will follow for discussion on the results, accessible via the investor relations website. Additionally, the company is planning an Investor Day in the first quarter of 2023 post the fourth quarter results in February, where executives will update on strategy and fiscal 2023 guidance, alongside product demonstrations.